{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=American+Society+of+Clinical+Oncology",
    "query": {
      "sponsor": "American Society of Clinical Oncology",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=American+Society+of+Clinical+Oncology&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=American+Society+of+Clinical+Oncology&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T12:11:51.105Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04754399",
      "title": "Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthralgia",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cannabidiol (CBD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2021-04-16",
      "completion_date": "2023-10-10",
      "has_results": true,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04754399"
    },
    {
      "nct_id": "NCT05912231",
      "title": "Ultrahypofractionation and Normal Tissue Toxicity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Female",
        "Breast Cancer Stage II",
        "Breast Cancer Stage III",
        "Myocardial Fibrosis"
      ],
      "interventions": [
        {
          "name": "Accelerated Proton Beam Radiation Therapy (PBT)",
          "type": "RADIATION"
        },
        {
          "name": "Accelerated Photon Radiation Therapy (XRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2023-08-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05912231"
    },
    {
      "nct_id": "NCT04589286",
      "title": "Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Pack Health's Digital Life Coaching (DLC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Electronic Handouts",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-12-29",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04589286"
    },
    {
      "nct_id": "NCT06089083",
      "title": "PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Gynecologic Cancer",
        "Gynecologic Neoplasm"
      ],
      "interventions": [
        {
          "name": "Physical function assessment",
          "type": "OTHER"
        },
        {
          "name": "Self-reported Assessments and Questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Surgery (Standard of Care, Non-Interventional)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 500,
      "start_date": "2023-10-18",
      "completion_date": "2033-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06089083"
    },
    {
      "nct_id": "NCT01647607",
      "title": "Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Young Women's Intervention (YWI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Physical Activity Intervention (PAI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 467,
      "start_date": "2012-06",
      "completion_date": "2017-12-20",
      "has_results": false,
      "last_update_posted_date": "2020-07-29",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647607"
    },
    {
      "nct_id": "NCT03801434",
      "title": "Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCR-JAK2 Fusion Protein Expression",
        "Blasts 20 Percent or Less of Peripheral Blood White Cells",
        "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells",
        "Blasts More Than 5 Percent of Peripheral Blood White Cells",
        "Blasts Under 20 Percent of Bone Marrow Nucleated Cells",
        "Chronic Eosinophilic Leukemia, Not Otherwise Specified",
        "Eosinophilia",
        "Hepatomegaly",
        "Hypereosinophilic Syndrome",
        "JAK2 Gene Mutation",
        "Splenomegaly",
        "TEL-JAK2 Fusion Protein Expression"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-11-15",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801434"
    },
    {
      "nct_id": "NCT01184885",
      "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Lymphoid Malignancies (New or Relapsed)",
        "Acute Lymphoblastic Leukemia",
        "Burkitt Lymphoma",
        "Lymphoblastic Lymphoma",
        "Mantle Cell Lymphoma",
        "Adult T-cell Leukemia/Lymphoma"
      ],
      "interventions": [
        {
          "name": "Hyper-CVAD",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-07",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01184885"
    },
    {
      "nct_id": "NCT00185965",
      "title": "CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "CPG 7909",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ronald Levy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-07",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-08-01",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00185965"
    },
    {
      "nct_id": "NCT03546686",
      "title": "Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Core Biopsy/Cryoablation",
          "type": "PROCEDURE"
        },
        {
          "name": "Breast Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 51,
      "start_date": "2019-11-12",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546686"
    },
    {
      "nct_id": "NCT00577642",
      "title": "Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2007-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-10-10T12:11:51.105Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577642"
    }
  ]
}